CN107595855A - Vardenafil oral formulations - Google Patents
Vardenafil oral formulations Download PDFInfo
- Publication number
- CN107595855A CN107595855A CN201710941413.3A CN201710941413A CN107595855A CN 107595855 A CN107595855 A CN 107595855A CN 201710941413 A CN201710941413 A CN 201710941413A CN 107595855 A CN107595855 A CN 107595855A
- Authority
- CN
- China
- Prior art keywords
- vardenafil
- oral formulations
- chewable tablets
- compound
- pharmaceutic adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Vardenafil oral formulations, it is characterized in that described oral formulations are chewable tablets, the chewable tablets forms by active component and suitable for the pharmaceutic adjuvant of chewable tablets, described active component is Vardenafil and the β oleananes 1 of 2 cyano group, 3 oxo 18, the nitrile of 12 diene 30 (I), the every Vardenafil containing 5~10mg, 10~15mg compounds (I);Described pharmaceutic adjuvant is made up of the filler for accounting for the disintegrant of pharmaceutic adjuvant gross mass 3 4%, 3 5% adhesive, 0.5 3% flavouring, 0.5 1% lubricant and surplus.
Description
Technical field:
The present invention relates to a kind of Vardenafil and the compound oral administration preparation of Enoxolone derivative.
Background technology:
Vardenafil (Vardenafil) is a kind of selective PDE5 inhibitor, by Bayer Bitterfeld GmbH (Bayer) and Ge Lansu
SmithKline (Glaxo Smith Kline) company develops, and compared with silaenafil, it has, and dosage is few, and onset time is express, safety
The characteristics of property is high, Chinese patent CN201110131028.5 discloses the 2- cyano group -3- oxygen as a kind of Enoxolone derivative
Generation -18 β-oleanane -1,12- diene -30- nitriles (I), and it has certain antitumor activity, but in the publication, the chemical combination
The antitumor activity and unobvious of thing.The chemical formula of the compound (I) is
We have found that compound (I) can increase the selective depression to PDE5 to Vardenafil in pilot experiments, therefore
A kind of properly mixed Enoxolone derivative and Vardenafil compound preparation are provided on the basis of this to be turned into the prior art urgently
Solve the problems, such as.
The content of the invention
The invention provides a kind of Vardenafil and -18 β of 2- cyano group -3- oxos-oleanane -1,12- diene -30- nitriles
(I) compound oral administration preparation, under study for action we have surprisingly found that, using a certain proportion of compound (I) and Vardenafil and
Its manufactured compound oral administration preparation, its therapeutic effect can be significantly improved, reduce the once used amount of Vardenafil, so as to
Reduce the generation of its side effect.
The invention provides a kind of Vardenafil oral formulations, it is characterized in that described oral formulations are chewable tablets, it is described
Chewable tablets forms by active component and suitable for the pharmaceutic adjuvant of chewable tablets, and described active component is Vardenafil and 2- cyanogen
- 18 β of base -3- oxos-oleanane -1,12- diene -30- nitriles (I), the every Vardenafil containing 5~10mg, 10~15mg
Compound (I);Described pharmaceutic adjuvant is by accounting for pharmaceutic adjuvant gross mass 3-4% disintegrant, 3-5% adhesive, 0.5-3%
Flavouring, 0.5-1% lubricant and surplus filler composition.
Described chewable tablets, it is characterised in that the disintegrant be selected from microcrystalline cellulose, low substituted hydroxy-propyl fiber, hand over
Join the one or more in polyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium.Preferred weight ratio 1:0.4~0.6:0.3~0.5
PVPP (cross-linked pvp), Ac-Di-Sol (crosslinking CMC-Na) and microcrystalline cellulose.
Described filler, selected from lactose, sorbierite, mannitol.It is preferred that lactose.
Described adhesive is selected from starch, pregelatinized starch, dextrin, maltodextrin, sucrose, Arabic gum, polyethylene
Alcohol, polyethylene glycol, polyvinylpyrrolidone (PVP), alginic acid and alginate, xanthans, hydroxypropyl cellulose and hydroxypropyl
Methylcellulose (HPMC), preferably weight is than 1:0.6~0.8:0.2~0.3 polyvinylpyrrolidone (PVP), pregelatinated
Starch and hydroxypropyl methyl cellulose
The lubricant is preferably magnesium stearate.
The flavouring is selected from sucrose, saccharin sodium, honey element, Aspartame, citric acid, tartaric acid, malic acid, Vitamin C
One or more in acid, xanthans, guar gum, tragacanth, preferred weight ratio 1:0.2~0.3 sucrose and citric acid.
Although under study for action it was found that 2- cyano group -3- oxos -18 β-oleananes-as Enoxolone derivative
1,12- diene -30- nitriles (I) itself without PDE5 inhibitor effect, but with Vardenafil composition compound oral administration preparation, can
To significantly improve Vardenafil as selectivity during PDE5 inhibitor, so as to reduce its adverse reaction, and according to animal
Experiment shows, when compound (I) is administered with Vardenafil with preferable proportion, can improve it to ED animal patterns
Therapeutic effect.Illustrate chewable tablets provided by the invention, by optimization formula, the selectivity of Vardenafil can be improved, reduce it
Side effect, in the treatment for diseases such as ED and pulmonary hypertensions, its therapeutic effect can be significantly improved..
Embodiment
All formulations example (every auxiliary material 200mg, common 200g) in terms of 1000
Preparation example 1~4, Vardenafil and -18 β of 2- methoxyl group -3- oxos-oleanane -1,12- diene -30- acid (letters
Claim compound (I)) compound chewable tablets
The chemical formula of compound (I) is as follows
The synthetic method of compound (I) is as described in CN201110131028.5.
The compound method of chewable tablets is as follows in preparation example:
(1) in prescription ratio, part supplementary material (main ingredient, adhesive, filler and disintegrant) is accurately weighed, crosses 100 mesh
Sieve, thoroughly mixing, the appropriate amount of ethanol for adding 50% prepares softwood, is pelletized with 24 mesh sieves, 60 DEG C of dryings, then with 24 mesh sieve whole grains.
(2) flavouring and lubricant are added in the particle after above-mentioned whole grain, is sufficiently mixed uniformly, trimmer weight, tabletting.
The PDEs Choice tests of Pharmacological Examples 1
PDE6 extracts from bovine retina, and PDE3 and PDE5 extract from rabbit platelet, and PDE4 extracts from male SD rat kidney,
PDE1 extracts from male SD rat Cerebral cortex, and PDE2 extracts from beasle dog adrenal gland
PDEs activity test methods
The storing solution for being respectively l00mM with DMSO compound concentrations by Vardenafil and compound (I), then shown according to the form below
Ratio dilutes the mixed solution of the obtained compound (I) of experimental group 1~7 and Vardenafil with purified water, experimental group 1~7
Mixed solution concentration is respectively l0mM, 1mM, 100 μM, l0 μM, 1 μM, l00nM, l0nM, 1nM, 0.1nM in terms of Vardenafil, real
8,9 solution of group are tested as Vardenafil and compound (I) storing solution are diluted into l0mM, 1mM, 100 μM, l0 μ with purified water respectively
M, 1 μM, the solution of l00nM, l0nM, 1nM, 0.1nM concentration.
According to different enzymes, different drug concentration gradients is selected, measure various concentrations suppress to live to the inhibitory activity of enzyme
Property calculates according to equation below.
In formula, CPMsample represents to contain testing compound in the buffer solution of kit simultaneously, enzyme and hydrolysis substrate
When read-out count value, CPMcontrol represented in buffer solution to the count value read-out by containing enzyme and hydrolysis substrate,
The count value read-out by hydrolysis substrate is comprised only in CPMblank buffer solutions.
IC50 (half maximal inhibitory are calculated by Prism softwares nonlinear regression
concentration)。
Packet and composition ratio situation such as following table (using Vardenafil weight as 100)
Experimental result is as follows
Test result indicates that it is right to significantly improve its when compound (I) is coordinated with Vardenafil with certain proportion
PDE5 selectivity.
Effect experiment in the body of Pharmacological Examples 2
2.1. animal packet
Using male mature rabbits, body weight 3.5-4.5kg, random packet, every group 10, packet is seen below with administrations
Table:
Group number | Administrations |
1 | (blank control) physiological saline 4ml/kg |
2 | (positive control) Vardenafil 10mg/kg |
3 | Vardenafil 5mg/kg+ compounds (I) 5mg/kg |
4 | Vardenafil 5mgkg+ compounds (I) 10mg/kg |
5 | Vardenafil 5mg/kg+ compounds (I) 15mg/kg |
6 | Compound (I) 10mg/kg |
2.3 method of testing
SNP (sodium nitroprussiate) as external source type NO donors is auricular vein drug administration by injection, and capacity 1ml/kg, parenteral solution is administered
SNP concentration be 0.1 μm of ol/L.
After rabbit is weighed, dosage regimen in capacity foregoing 2.1 is administered by 4ml/kg and carries out carry out gastric infusion, and in gavage
The laggard rows of 1h are administered and carry out SNP auricular vein injections, 5,10,15,30,45 measurement penis length (exposed portion) after injection, and
Penis length maximum is recorded, as a result see the table below
Test result indicates that when Vardenafil and compound (I) are with 1:, can be notable when 1.5~2 ratio is administered simultaneously
The degree of erection of the Conscious Rabbit under the conditions of auricular vein drug administration by injection SNP is improved, so as to improve Vardenafil for ED
Therapeutic effect, and the effect only using above-mentioned preferred proportion scope when can just be embodied, more or less compounds
(I) without this effect, and simultaneously effect in the case of compound alone (I).
Claims (6)
1. Vardenafil oral formulations, it is characterized in that described oral formulations are chewable tablets, the chewable tablets by active component and
Formed suitable for the pharmaceutic adjuvant of chewable tablets, described active component is Vardenafil and 2- cyano group -3- oxos -18 β-olive
Alkane -1,12- diene -30- nitriles (I), the every Vardenafil containing 5~10mg, 10~15mg compounds (I);Described is medicinal
Auxiliary material is by accounting for pharmaceutic adjuvant gross mass 3-4% disintegrant, 3-5% adhesive, 0.5-3% flavouring, 0.5-1% profit
Lubrication prescription and the filler of surplus composition.
2. Vardenafil oral formulations as claimed in claim 1, it is characterised in that the disintegrant is selected from weight than 1:0.4~
0.6:0.3~0.5 PVPP (cross-linked pvp), Ac-Di-Sol (crosslinking CMC-Na) and micro-
Crystalline cellulose.
3. Vardenafil oral formulations as claimed in claim 1, it is characterised in that the preferred lactose of described filler.
4. Vardenafil oral formulations as claimed in claim 1, it is characterised in that described adhesive is preferably weight than 1:0.6
~0.8:0.2~0.3 polyvinylpyrrolidone (PVP), pregelatinized starch and hydroxypropyl methyl cellulose.
5. Vardenafil oral formulations as claimed in claim 1, it is characterised in that the lubricant is preferably magnesium stearate.
6. Vardenafil oral formulations as claimed in claim 1, it is characterised in that the flavouring preferred weight ratio 1:0.2~
0.3 sucrose and citric acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710941413.3A CN107595855A (en) | 2017-10-11 | 2017-10-11 | Vardenafil oral formulations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710941413.3A CN107595855A (en) | 2017-10-11 | 2017-10-11 | Vardenafil oral formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107595855A true CN107595855A (en) | 2018-01-19 |
Family
ID=61068129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710941413.3A Withdrawn CN107595855A (en) | 2017-10-11 | 2017-10-11 | Vardenafil oral formulations |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107595855A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002147A1 (en) * | 1997-07-09 | 1999-01-21 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
CN102250189A (en) * | 2011-05-20 | 2011-11-23 | 中国药科大学 | Glycyrrhetic acid derivative with 1, 12-diene-3-ketone skeleton, its preparation method and medicinal uses |
-
2017
- 2017-10-11 CN CN201710941413.3A patent/CN107595855A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002147A1 (en) * | 1997-07-09 | 1999-01-21 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
CN102250189A (en) * | 2011-05-20 | 2011-11-23 | 中国药科大学 | Glycyrrhetic acid derivative with 1, 12-diene-3-ketone skeleton, its preparation method and medicinal uses |
Non-Patent Citations (1)
Title |
---|
王震: "选择性PDE5抑制剂TPN729的成药性评价及临床前药效学研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60211937T2 (en) | USE OF FLIBANSERIN IN THE TREATMENT OF SEIZURES OF SEXUAL DEMAND | |
CN105106203B (en) | Pharmaceutical composition of Vonoprazan fumarate and preparation method thereof | |
US20070123540A1 (en) | Sexual desire enhancing medicaments comprising benzimidazolone derivatives | |
CN101175487B (en) | Pharmaceutical use of ebselen | |
EP1732559B1 (en) | Methods of treatment using eszopiclone | |
US20080242679A1 (en) | Benzimidazolone Derivatives For the Treatment of Premenstrual and Other Female Sexual Disorders | |
KR102246657B1 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
US20210030786A1 (en) | Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate | |
CN101683324A (en) | Oral disintegrative tablet of sildenafil citrate and preparation method thereof | |
AU2022220869A1 (en) | Irak4 degraders and uses thereof | |
JP2015013857A (en) | Coated formulation | |
CN105395504B (en) | A kind of flunarizine hydrochloride matrix sustained release tablet and preparation method thereof | |
KR20130114948A (en) | Liquidic formulation for oral administraion comprising ambroxol, levodropropizine and buffer, and method for preparing the same | |
CN107595855A (en) | Vardenafil oral formulations | |
EP3322402B1 (en) | Compositions of midazolam for buccal administration in the treatment of seizures to obtain rapid onset of action | |
CN107595848A (en) | Tadalafei oral formulations | |
CN107595856A (en) | Enoxolone derivative and Vardenafil compound chewable tablets | |
CN107468663A (en) | The compound chewable tablets of Tadalafei and Enoxolone derivative | |
ES2295588T3 (en) | USE OF AMBROXOL FOR THE TREATMENT OF CHRONIC PAIN. | |
WO2006072415A1 (en) | Use of selected cgrp antagonists for controlling menopausal hot flashes | |
CN104622842B (en) | A kind of calcium hydrophenyl sulfonate capsule and preparation method thereof | |
US20050014845A1 (en) | Ambroxol for the treatment of epilepsy | |
CN107714705A (en) | A kind of silaenafil oral formulations | |
CN107714704A (en) | 30 sour chewable tablets of silaenafil and 2 methoxyl group, 3 oxo, 18 β oleananes, 1,12 diene | |
KR102083621B1 (en) | Oral liquid formulation having improved stability comprising ambroxol and levodropropizine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180119 |
|
WW01 | Invention patent application withdrawn after publication |